Evidence Archives

2019 ASCO FLEX Poster
Gallery
2019 ASCO FLEX Poster

Evidence, FLEX TIPS, MammaPrint, Other

2019 ASCO FLEX Poster

AUTHORS: Gordan Srkalovic, Adam Brufsky, Jennifer Crozier, Mehran Habibi, Pat Read More

kevin2024-03-25T08:51:45-07:00June 4th, 2019|Evidence, FLEX TIPS, MammaPrint, Other|

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study
Gallery
Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe

Strong Impact of MammaPrint and BluePrint on Treatment Decisions in Luminal Early Breast Cancer: Results of the WSG-PRIMe Study

PUBLICATION: Breast Cancer Res Treat. (2019) 175: 389. https://doi.org/10.1007/s10549-018-05075-x. AUTHORS: Read More

kevin2024-03-25T11:24:02-07:00June 1st, 2019|Adjuvant, BluePrint, Evidence, MammaPrint, WSG-PRIMe|

NBRST: ER-positive basal-type breast cancers, respond like TNBC

NPJ Breast Cancer, April 2019 Author: Groenendijk et al.

Read More

Karen Guzdzial2024-04-16T11:49:27-07:00April 21st, 2019|Evidence, NBRST, Neoadjuvant|

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers
Gallery
Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

Evidence, NBRST, Neoadjuvant

Estrogen Receptor Variants in ER-Positive Basal-Type Breast Cancers Responding to Therapy Like ER-Negative Breast Cancers

PUBLICATION: npj Breast Cancer; volume 5, Article number: 15 (2019). Read More

kevin2024-03-25T08:54:30-07:00April 18th, 2019|Evidence, NBRST, Neoadjuvant|

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis
Gallery
Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

BluePrint, Evidence, Other, Validation

Reclassification of Early Stage Breast Cancer Into Treatment Groups by Combining the Use of Immunohistochemistry and Microarray Analysis

PUBLICATION: Vol 115 No 3/4 (2019): South African Journal of Read More

kevin2024-03-25T08:56:28-07:00March 27th, 2019|BluePrint, Evidence, Other, Validation|

2018 SABCS FLEX Trials in Progress Poster
Gallery
2018 SABCS FLEX Trials in Progress Poster

Evidence, FLEX TIPS, MammaPrint, Other

2018 SABCS FLEX Trials in Progress Poster

AUTHORS: Adam M. Brufsky, Jennifer A. Crozier, Ian Grady, Thomas Read More

kevin2024-03-25T08:56:58-07:00December 5th, 2018|Evidence, FLEX TIPS, MammaPrint, Other|

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2
Gallery
BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other

BluePrint Luminal subtype predicts non-response to HER2-targeted therapies- I-SPY2

AACR, Poster 2612 AUTHORS: Pei Rong Evelyn Lee, Zelos Zhu, Read More

kevin2024-03-27T10:20:24-07:00April 18th, 2018|BluePrint, Evidence, HER2-positive, I-SPY2, Neoadjuvant, Other|

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay
Gallery
Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

Adjuvant, Evidence, MammaPrint, PROMIS

Association of 70-Gene Signature Assay Findings With Physicians’ Treatment Guidance for Patients With Early Breast Cancer Classified as Intermediate Risk by the 21-Gene Assay

PUBLICATION: JAMA Oncol. 2018; 4(1):e173470. doi:10.1001/jamaoncol.2017.3470. AUTHORS: Michaela Tsai, MD; Read More

kevin2024-03-25T08:57:37-07:00January 11th, 2018|Adjuvant, Evidence, MammaPrint, PROMIS|

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades
Gallery
Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

Endocrine, Evidence, MammaPrint, STO-3

Use of Molecular Tools to Identify Patients With Indolent Breast Cancers With Ultralow Risk Over 2 Decades

PUBLICATION: JAMA Oncol. 2017;3(11):1503-1510. doi:10.1001/jamaoncol.2017.1261. AUTHORS: Laura J. Esserman, MD, Read More

kevin2024-06-28T12:13:13-07:00November 2nd, 2017|Endocrine, Evidence, MammaPrint, STO-3|

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk
Gallery
Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

Endocrine, Evidence, MammaPrint, STO-3

Tamoxifen Therapy Benefit for Patients with 70-gene Signature High and Low Risk

PUBLICATION: Breast Cancer Res Treat (2017) 166: 593. https://doi.org/10.1007/s10549-017-4428-9. AUTHORS: Read More

kevin2024-03-25T08:59:17-07:00November 1st, 2017|Endocrine, Evidence, MammaPrint, STO-3|